Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients-Reference-Cited by-同舟云学术

Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients

Published:2017-11-19 Issue:3 Volume:74 Page:315-321
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Puértolas Isabel^ORCID,Frutos Pérez-Surio Alberto,Alcácera María Aránzazu,Andrés Raquel,Salvador María del Tránsito

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-017-2365-5/fulltext.html

Reference34 articles.

1. Hosseinzadeh A, Thompson PR, Segal BH, Urban CF (2016) Nicotine induces neutrophil extracellular traps. J Leukoc Biol 100:1105–1112

2. Kourlaba G, Diopoulos MA, Pectasides D et al (2015) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer 23:2045–2051

3. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

4. Caggiano V, Weiss RV, Rickert TS et al (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924

5. Raposo CG, Marin AP, Barón MG (2006) Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced neutropenia. Clin Transl Oncol 8:729–734

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Originator and Biosimilar G-CSF as Primary Prophylaxis in DLBCL: A Cohort Study and Meta-Analysis;2023-09-11

2. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis;Supportive Care in Cancer;2020-07-03

3. Author’s Reply to Puértolas-Tena and Pérez-Surio: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”;BioDrugs;2019-10

4. Comment on: “Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis”;BioDrugs;2019-10

5. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis;BioDrugs;2019-06-03